206 related articles for article (PubMed ID: 37314514)
41. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
[TBL] [Abstract][Full Text] [Related]
42. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
Wei H; Wu F; Mao Y; Zhang Y; Leng G; Wang J; Zhang W; Wang T
Jpn J Clin Oncol; 2022 Apr; 52(4):331-345. PubMed ID: 35106596
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
Boldrin E; Gaffo E; Niedermayer A; Boer JM; Zimmermann M; Weichenhan D; Claus R; Münch V; Sun Q; Enzenmüller S; Seyfried F; Demir S; Zinngrebe J; Cario G; Schrappe M; Den Boer ML; Plass C; Debatin KM; Te Kronnie G; Bortoluzzi S; Meyer LH
Blood; 2021 Nov; 138(20):1953-1965. PubMed ID: 34098582
[TBL] [Abstract][Full Text] [Related]
45. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
46. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
47. Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.
Mirji G; Bhat J; Kode J; Banavali S; Sengar M; Khadke P; Sait O; Chiplunkar S
Leuk Res; 2016 Jun; 45():33-9. PubMed ID: 27070758
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
49. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
50. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
51. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
52. Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.
Tomassen T; Weidema ME; Hillebrandt-Roeffen MHS; van der Horst C; ; Desar IME; Flucke UE; Versleijen-Jonkers YMH
Immunol Res; 2022 Apr; 70(2):256-268. PubMed ID: 35043369
[TBL] [Abstract][Full Text] [Related]
53. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
54. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
55. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
56. The significance of PD-1/PD-L1 imbalance in ulcerative colitis.
Shi W; Zhang Y; Hao C; Guo X; Yang Q; Du J; Hou Y; Cao G; Li J; Wang H; Fang W
PeerJ; 2023; 11():e15481. PubMed ID: 37273534
[TBL] [Abstract][Full Text] [Related]
57. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
58. Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis.
Wang Y; Lu H; Li M
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):74-78. PubMed ID: 36800834
[TBL] [Abstract][Full Text] [Related]
59. [PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia].
Li JH; Pang NN; Zhang ZH; Zhang R; Chen G; Qu JH
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):198-203. PubMed ID: 28395442
[No Abstract] [Full Text] [Related]
60. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]